
==== Front
Curr Neuropharmacol
Curr Neuropharmacol
CN
Current Neuropharmacology
1570-159X
1875-6190
Bentham Science Publishers

37646225
CN-22-2157
10.2174/1570159X21666230830142554
Medicine, Neurology, Pharmacology, Neuroscience
Recombinant Antibody Fragments for Neurological Disorders: An Update
Manoutcharian Karen 1
Gevorkian Goar 1*
1 Instituto de Investigaciones Biomedicas, Universidad Nacional Autonoma de Mexico (UNAM), CDMX, Mexico
* Address correspondence to this author at the Instituto de Investigaciones Biomedicas, Universidad Nacional Autonoma de Mexico (UNAM), Apartado Postal 70228, Cuidad Universitaria, Mexico DF, CP 04510, Mexico; E-mail: gokar@unam.mx
31 8 2023
2024
22 13 21572167
11 4 2023
15 6 2023
13 7 2023
© 2024 The Author(s). Published by Bentham Science Publishers
2024
The Author(s)
https://creativecommons.org/licenses/by/4.0/ © 2024 The Author(s). Published by Bentham Science Publishers. This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode.
Recombinant antibody fragments are promising alternatives to full-length immunoglobulins, creating big opportunities for the pharmaceutical industry. Nowadays, antibody fragments such as antigen-binding fragments (Fab), single-chain fragment variable (scFv), single-domain antibodies (sdAbs), and bispecific antibodies (bsAbs) are being evaluated as diagnostics or therapeutics in pre-clinical models and in clinical trials. Immunotherapy approaches, including passive transfer of protective antibodies, have shown therapeutic efficacy in several animal models of Alzheimer’s disease (AD), Parkinson’s disease (PD), frontotemporal dementia (FTD), Huntington’s disease (HD), transmissible spongiform encephalopathies (TSEs) and multiple sclerosis (MS). There are various antibodies approved by the Food and Drug Administration (FDA) for treating multiple sclerosis and two amyloid beta-specific humanized antibodies, Aducanumab and Lecanemab, for AD. Our previous review summarized data on recombinant antibodies evaluated in pre-clinical models for immunotherapy of neurodegenerative diseases. Here, we explore recent studies in this fascinating research field, give an update on new preventive and therapeutic applications of recombinant antibody fragments for neurological disorders and discuss the potential of antibody fragments for developing novel approaches for crossing the blood-brain barrier (BBB) and targeting cells and molecules of interest in the brain.

Keywords

Nanobody
intrabody
antibody fragment
Alzheimer’s disease
Parkinson’s disease
Huntington’s disease
immunotherapy
==== Body
pmc1 INTRODUCTION

Recombinant antibody fragments are promising alternatives to full-length immunoglobulins, creating huge opportunities for the pharmaceutical industry. Higher solubility, stability, specificity and affinity, reduced immunogenicity, the ability to refold after heat denaturation, the capacity to target hidden epitopes and cross the blood-brain barrier (BBB), and inexpensive large-scale production are the advantages of antibody fragments compared to conventional monoclonal antibodies [1-14]. In addition, antibody fragments do not induce microglia FcγR-mediated pro-inflammatory response and tissue damage in the CNS because they lack the Fc portion of the immunoglobulin molecule [15, 16].

Nowadays, there is a handful of recombinant antibody fragments approved by the FDA for therapeutic use in individuals with diabetic retinopathy, age-related macular degeneration, Chron's disease, moderate to severely active rheumatoid arthritis, acquired thrombotic thrombocytopenic purpura and thrombosis (The Antibody Society. Therapeutic monoclonal antibodies approved or in review in the EU or US. www.antibodysociety.org/resources/approved-antibodies). Also, many antibody fragments such as antigen-binding fragments (Fab), single-chain fragment variable (scFv) consisting of the antigen-binding domains of Ig heavy (VH) and light (VL) chain regions connected by a flexible peptide linker, single-domain antibody fragments (sdAbs) like camelid heavy-chain variable domains (VHHs) and shark variable new antigen receptor (VNARs), and bispecific antibodies (bsAbs) are being evaluated as diagnostics or therapeutics in pre-clinical models and clinical trials of cancer as well as infectious, neurological, and autoimmune diseases (11, 12, 14, www.clinicaltrials.gov).

Immunotherapy approaches, including passive transfer of protective antibodies and their fragments, have shown therapeutic efficacy in several animal models of Alzheimer’s disease (AD), Parkinson’s disease (PD), frontotemporal dementia (FTD), Huntington’s disease (HD), transmissible spongiform encephalopathies (TSEs) and multiple sclerosis (MS) [17-26]. It has been demonstrated that these molecules may target toxic extra- and intracellular misfolded proteins involved in the pathogenesis of AD, PD, FTD, HD, or TSEs and toxic immune cells participating in the pathogenesis of MS [23, 25, 27-31].

In our previous review, we summarized data on recombinant antibody fragments evaluated until 2016 in pre-clinical models and clinical studies for immunotherapy of neurodegenerative diseases [5]. Here, we explore recent studies in this fascinating research field and give an update on new preventive and therapeutic applications of recombinant antibody fragments for neurological disorders. In addition, we discuss the potential of antibody fragments for developing novel approaches for crossing the blood-brain barrier (BBB) and targeting cells and molecules of interest in the brain.

2 ALZHEIMER’S DISEASE (AD)

AD, the most common cause of dementia, is a multifactorial disease and is considered to be a result of several pathological events, both in the periphery and in the brain, including chronic local or systemic inflammation, cerebrovascular dysfunction, oxidative stress, mitochondrial dysfunction, amyloidosis, synaptic and neuronal network dysfunction, metabolic syndrome as well as many disrupted cell signaling pathways [revised extensively elsewhere, 32-35]. The accumulation of extracellular and intracellular amyloid-beta (Aβ) peptide aggregates and neurofibrillary tangles, consisting of the hyperphosphorylated microtubule-associated protein tau, in the human brain has been hypothesized to play a central role in the neuropathology of AD, and efforts have been made to generate antibody-based therapeutics for targeting Aβ and tau aggregates [5, 24, 26, 36, 37]. Here, we discuss recent studies reporting the use of different formats of antibody fragments in in vivo pre-clinical models and clinical studies for immunotherapy of AD (Table 1).

2.1 New Studies on Further Characterization and Application of Already Reported Recombinant Antibody Fragments

ScFv-h3D6 is a recombinant antibody fragment derived from a fully humanized and extensively evaluated in clinical trials monoclonal anti-Aβ antibody bapineuzumab. We described this fragment’s development and protective properties in our previous review [5]. Subsequently, the authors modified the scFv-h3D6 by introducing mutations in the VH domain and demonstrated that the improved variants are of high therapeutic interest [38]. Likewise, the authors observed that the scFv-h3D6 inhibits human astrocyte's uptake of toxic Aβ oligomers in vitro [39]. Importantly, it has been shown previously that astrocytes accumulate and spread toxic Aβ species because of endosomal/lysosomal fault and inefficient digesting caused by Aβ, leading to microvesicle-induced apoptosis of neurons [40]. Interference in Aβ binding and uptake by astrocytes using scFv-h3D6 antibody may be one of the mechanisms explaining the protective properties of this fragment widely used previously [39]. To improve the production of scFv-h3D6 fragment, the authors used the yeast Pichia pastoris. They demonstrated that scFv-h3D6 obtained in this system could reduce amyloid burden in the 3xTg-AD mouse brain. It does not contain LPS contamination or conformational changes observed in recombinant proteins obtained in E. coli [41]. These findings are important for the pharmaceutical industry for large-scale production of scFv fragments that increasingly attract more attention.

Also, the authors further investigated the protective mechanism of scFv-h3D6. They found that it crosses the BBB after a single intraperitoneal (i.p.) injection in 3xTg-AD mice and decreases Aβ levels in the brain [42, 43]. scFv-h3D6 and Aβ were detected in neurons and microglia, suggesting that scFv-h3D6 may cross the cell membrane and that microglia can phagocyte scFv-Aβ complex [42, 43]. Surprisingly, the authors also found endothelial cells with intracellular scFv-h3D6 and Aβ, indicating the involvement of the endothelial cells in the process [42]. Importantly, the authors observed the reduction of intracellular Aβ burden and prevention of neuronal loss [43]. Inflammatory markers in the brain and kidney or liver side effects were not documented in treated animals, and improvement in spatial memory was observed [43]. Then, an in vivo longitudinal study using scFv-h3D6 was performed: 5-month-old 3xTg-AD mice received monthly i.p. injections for seven months, and four magnetic resonance imaging and spectroscopy (MRI/MRS) studies were performed at 5, 7, 9, and 12 months of age [44]. Authors documented the reduction in Aβ and proinflammatory cytokines levels in scFv-treated mice compared with control 3xTg-AD mice, and no side effects were observed after multiple doses [44]. When administered to 22-month-old female 3xTg-AD mice by i.p. injection every 3 days for 15 days, scFv-h3D6 antibody ameliorated Aβ burden in the hippocampus, suggesting the therapeutic potential of this fragment in old animals with abundant amyloid accumulation [45]. As in previous studies, scFv-h3D6 co-localized with Aβ inside the CA3 neurons, indicating that it may also reduce intraneuronal Aβ [45]. These findings suggest that the immunotherapy protocols using Aβ-specific scFvs represent a promising therapeutic tool for Aβ elimination without side effects after peripheral injection.

In our previous review, we summarized reports from Dr. Sierks’s group on selecting and characterizing a number of scFvs specifically binding to Aβ, tau, or TDP-43 [5]. Recently, some of these fragments were used to develop blood-based biomarkers for the early diagnosis of AD [46, 47]. The authors analyzed longitudinal human plasma samples from individuals with AD and mild cognitive impairment (MCI) and controls and demonstrated the capacity of scFvs to differentiate AD cases from controls, suggesting that antibody fragments may be used as blood-based biomarkers for AD.

Likewise, two previously reported single-domain camelid VHH antibody fragments, designated PrioAD12 and PrioAD13 and specifically binding to oligomeric Aβ1-40 and Aβ1-42, respectively, were shown to detect Aβ oligomers in the retina and blood of APP/PS1 mice before amyloid accumulation in the brain and before the cognitive decline, pointing to the potential of such nanobodies as early diagnostic tools for AD [48].

2.2 Novel Recombinant Antibody Fragments

Two novel camelid single-domain antibodies (VHHs), designated R3VQ and A2 and specifically binding to Aβ and tau, respectively, were shown to cross the BBB, diffuse in the brain after intravenous administration, and bind to extracellular plaques and intracellular tangles [49]. Subsequently, R3VQ VHH was used to generate imaging probes for magnetic resonance imaging (MRI) that were shown to cross the BBB and label Aβ deposits after intravenous injection [50]. These new fragments are very promising for developing diagnostics and therapeutics for AD.

Sebollela and collaborators identified a human scFv, NUsc1, which distinguished Aβ oligomers from monomeric and fibrillar Aβ and reduced oligomeric Aβ-induced oxidative stress and tau hyperphosphorylation in cultured neurons [51]. NUsc1 scFv is also bound to Aβ in brain extracts from APP-transgenic mice and individuals with AD [51]. In addition, NUsc1 scFv recognized Aβ oligomers in fixed AD brain samples [51]. It is known that Aβ oligomers are the most toxic and pathogenic aggregates found in the brain at early stages before the build-up of amyloid plaques, and molecules targeting oligomeric Aβ are of great importance for AD therapy [52]. Subsequently, the authors cloned NUsc1 into the adeno-associated viral vector (AAV) and demonstrated that the treatment with AAV-NUsc1 prevents oligomeric Aβ-induced memory impairment and reverses memory deficits in old APPswe/PS1ΔE9 mice [53]. These results indicate that viral vector-mediated delivery of Aβ-specific antibody fragments is a viable therapeutic approach in Alzheimer's disease. Importantly, nowadays, many AAV vectors are approved by the FDA and are widely used for gene therapy in humans.

Hu and collaborators isolated a novel Aβ-specific scFv17 fragment after screening an immune mouse scFv library and demonstrated its protective properties in APP/PS1 transgenic mice after intracranial injection [54].

Also, efforts have been made to produce and characterize recombinant antibody fragments targeting pathological forms and toxic aggregates of tau. An scFv antibody fragment, designated scFv-MC1 and based on the variable heavy (VH) and variable light (VL) chains of the well-characterized anti-tau monoclonal antibody MC1, was constructed, cloned into the AAV, and shown to reduce tau pathology after intracranial injection in adult JNPL3 transgenic mice, expressing human P301L-mutant tau [55]. Subsequently, the authors demonstrated that a single intramuscular injection of AAV1-scFvMC1 significantly reduces insoluble and soluble tau aggregates in the brain of two different tau transgenic mice, JNPL3 and P301S [56]. The authors detected scFvMC1 in the microglia, and, importantly, no inflammatory molecules were detected in the brain, suggesting the therapeutic potential of anti-tau scFv for AD and other tauopathies without side effects [56]. AT8-scFv fragment, based on the VL and VH regions of another well-characterized anti-phospho-Tau (Ser202, Thr205) monoclonal antibody AT8, was cloned into the AAV and shown to cross the BBB, infect neurons and express AT8-scFv for at least 22 weeks [57]. Two other tau-specific single-domain antibodies, VHH-E4-1, and its improved variant Z70, binding to the microtubule-binding domain (MTBD) of tau were shown to prevent tau fibrils assembly in vitro and inhibit tau seeding in the transgenic mouse model THY-tau 30 [58].

It has been reported that alternative splicing generates two major isoforms of tau containing either 3 or 4 repeats (R) segments, and both forms are detected in the brain of AD and other tauopathies patients; however, few studies were dedicated to the development of therapeutic strategies for targeting these toxic aggregates [59]. A scFv antibody designated 5F10 and selectively binding to the 3Rtau has been developed and fused to the LDL receptor-binding domain of apolipoprotein B (apoB) for enhancing the BBB crossing [60]. The authors demonstrated that the 5F10 antibody reduces the 3RTau accumulation and ameliorates behavioral deficits in a transgenic mouse model of tauopathy; notably, these mice accumulate intraneuronal 3RTau in the hippocampus and neocortex mimicking the accumulation in the AD brain [60].

To decrease the amyloidogenic processing of APP, various β-site amyloid precursor protein cleaving enzyme 1 (BACE-1) inhibitors have been explored as potential disease-modifying drugs for AD [61]. Likewise, a single chain antibody VHH-B9 has been isolated from an immune anti-human BACE-1 phage display VHH library and shown to effectively inhibit neuronal BACE-1 in primary neuronal cultures and reduce astrogliosis and microgliosis, Aβ burden, and cognitive deficits in an APP/Tg mouse model of AD after systemic AAV-mediated delivery [62].

An interesting approach has been developed recently by Dr. Sierks’s group. Since previous studies have shown that selectively inhibiting BACE-1 processing of APP and increasing non-amyloidogenic processing of APP by promoting α-secretase cleavage might have therapeutic importance for AD [63, 64], Sierks and collaborators generated a bispecific recombinant antibody fragment, diabody, combining a scFV, named iBsec1 and binding to BACE-1, and another scFv, named Asec1a that has been shown to promote non-amyloidogenic processing of APP [65]. The obtained bispecific diabody, after fusion with the low-density lipoprotein receptor-binding domain of the apolipoprotein B for enhancing the transfer across the BBB, was capable of reducing amyloid burden in APP/PS1 transgenic mice [65]. In addition, the authors documented increased survival of mice treated with the diabody while mice treated with iBsec1 showed no change in total mortality, suggesting that the simultaneous inhibition of BACE-1 and stimulation of the α-secretase processing of APP may be a more advantageous therapeutic approach for AD [65].

Recently, addressing the multifactorial origin of AD, Zhao and collaborators developed a multivalent nanobody conjugate PNBIL by linking an Aβ-specific nanobody covalently with a rigid, ROS scavenging scaffold poly(deca-4,6-diynedioic acid) [66]. The recombinant nanobody had an Aβ33-42 peptide sequence grafted into the third complementary-determining region (CDR3) and a fragment of human interleukin-1β, thus allowing the binding to the amyloid aggregates, inhibition of Aβ aggregation and effective Aβ clearance by microglia [66]. In addition, the ROS scavenging scaffold confers a long-term inhibition of oxidative stress and inflammation [66]. The protective potential of this multi-target construct has been confirmed in two APP/Tg mouse models of AD [66].

3 PARKINSON’S DISEASE (PD)

PD is the second most common neurodegenerative disease, and, as in the case of AD, multiple genetic and environmental factors, including oxidative stress, mitochondrial dysfunction, inflammation, gut dysbiosis, glymphatic system impairment, and the accumulation of pathological aggregates of α-synuclein (α-syn) in the Lewy bodies and Lewy neurites with the subsequent progressive loss of dopaminergic neurons in the brain, were described [revised extensively elsewhere, 34, 67-70]. Immunotherapeutic approaches targeting toxic α-syn aggregates are currently being evaluated in pre-clinical models [67, 71, 72]. All the above-discussed properties of recombinant antibody fragments and the possibility of intracellular expression make them suitable candidates for future therapies for PD.

After publishing our previous review [5], new anti-α-syn antibody fragments were generated and evaluated in vitro and in vivo. Two scFvs, scFv-pF and scFv-pC, were constructed using the VH and VL sequences of a previously described conformation-specific anti-α-syn monoclonal antibody (Syn-F2) [73]. The authors showed that both scFvs specifically bind to α-syn fibrils and oligomers but not to monomers and detected intracellular aggregates in the brain from individuals with Lewy body pathology [73]. Furthermore, scFv-pF and scFv-pC were capable of inhibiting the seeding of α-syn aggregation and reducing α-syn toxicity in a SH-SY5Y cell model of PD [73]. In addition, the authors developed an improved method for purifying antibody fragments from inclusion bodies and demonstrated its feasibility for the scFv-pF, shown to bind to the α-syn C-terminal region [74].

Fassler and collaborators isolated a novel scFv antibody designated sMB08 after the screening of an antibody fragment library against human α-syn and demonstrated that the sMB08 antibody fragment binds with a high affinity to both human and mouse α-syn oligomers and pre-formed fibrils (PFF), detects α-syn in the substantia nigra and cortex of patients with PD, inhibits α-syn aggregation in vitro, inhibits the toxicity of α-syn oligomers and PFF in SH-SY5Y cells, enters neurons and co-localize with α-syn aggregates, attenuates uptake of α-syn oligomers and PFF in human PBMCs and mouse microglia and down-regulates in a dose-dependent manner pro-inflammatory cytokines (TNF-α, IL-6) expression by microglia after exposure to PFF [75]. After intranasal administration, the sMB08 antibody fragment attenuated neuroinflammation in mice that received an intracranial injection of α-syn PFF [75]. Likewise, sMB08 attenuated motor dysfunction after intranasal administration in the rotenone rat model of PD [75].

A single domain antibody Nbα-syn01 was selected after screening an immune camelid VHH phage display library against monomeric α-syn [76]. The authors demonstrated that Nbα-syn01 binds to the N-terminal region of α-syn peptide, known to participate in α-syn aggregation in vitro and in vivo [76]. Also, Nbα-syn01 had a higher affinity towards α-syn fibrils than a monomeric form, detected Lewy bodies in brain samples from individuals with PD, and inhibited α-syn aggregation and toxicity in SH-SY5Y cells [76].

Mutations in the gene coding for leucine-rich repeat kinase 2 (LRRK2) have been linked with the inherited forms of PD, and the protein is considered an attractive target for immunotherapy of the disease [77-79]. This enzyme has two catalytic activities: GTPase activity mediated by the Roc domain and Ser/Thr protein kinase activity; the latter is considered particularly interesting for the drug development for PD [80]. Although ATP-competitive inhibitors are currently approved by FDA, long-term inhibition of LRRK2 with these molecules was associated with toxic side effects, including kidney and lung abnormalities [80, 81]. Therefore, designing molecules that bind outside the ATP-binding pocket represents an interesting and promising approach. With this hypothesis in mind, Singh and collaborators isolated nanobodies binding to a different region of the LRRK2 and capable of inhibiting the kinase activity in human embryonic kidney 293 (HEK293) cells overexpressing LRRK2 [81].

4 HUNTINGTON’S DISEASE (HD)

HD is an autosomal dominant inherited progressive neurodegenerative disorder caused by a trinucleotide repeat expansion in the huntingtin gene resulting in polyglutamine repeats-bearing mutant huntingtin (mhtt) accumulation in the neuronal nuclei and processes and subsequent neuronal loss [82, 83]. Recombinant intracellular antibody-mediated modulation of toxic mhtt aggregates represents an alternative therapeutic approach for HD [5, 30, 84, 85]. In our previous review, we summarized studies reporting various htt-targeting antibody fragments tested in vitro and in vivo [5]. Subsequently, new fragments were developed and explored. Amaro and Henderson selected a single-chain intrabody, INT41, that bound to the proline-rich region (PRR) of huntingtin and demonstrated that it could inhibit aggregation of transiently overexpressed mhtt in HEK293T cells [86]. After cloning into the AAV6 vector, the rAAV6-INT41 was administered bilaterally into the striatum of 5-week-old R6/2 mice, a transgenic mouse model widely used to study HD [86]. The authors observed that INT41 ameliorates mhtt-induced cognitive impairment and reduces aggregate formation in the striatum of treated animals [86].

5 NOVEL PLATFORMS

To enhance immunotherapy efficacy, the development of new platforms for therapeutic antibody application has been the primary goal of scientists and the pharmaceutical industry in recent years.

Perche and collaborators demonstrated that intracranial injection of three different Aβ-specific scFV mRNA polyplexes (cationic polymer-based complexes) significantly decreases Aβ accumulation in an acute amyloidosis model but not in a transgenic model of AD [87]. The authors observed that the mRNA-loaded polyplex nanomicelle platform allows efficient transfection of primary neurons and leads to detectable scFv mRNA expression in the brain during 48h. These results are interesting for further development of mRNA-based immunotherapeutic protocols for neurological disorders.

Another interesting approach has been proposed by Xie and collaborators [88]. In the Fab region of the above-described 3D6 monoclonal anti-Aβ antibody, positively charged primary amino groups were coupled with citraconic anhydride (Cit) through an amidation reaction, resulting in a negatively charged citraconylated-Fab (Cit-Fab) [88]. Then this charge-converted anionic Fab antibody fragment was coupled with a cationic poly(ethylene glycol)-poly(l-lysine) (PEG-PLL) block copolymer giving polymeric nanomicelles (PMs) [88]. The authors showed that 41-fold enhanced brain accumulation was achieved after peripheral injection of 3D6-Fab PMs compared with free 3D6-Fab [88]. In addition, 3D6-Fab PMs were capable of inhibiting Aβ1-42 aggregation in APP/Tg mice [88]. These findings are very promising because the use of nanomicelles may allow reducing substantially the amount of recombinant antibody dose and the frequency of application in patients.

Because the BBB is an obstacle to antibody passage into the brain, efforts were made to overcome it [89]. An interesting approach has been developed where anti-transferrin receptor (TfR) antibody fragments were used as a shuttle for the transport of molecules of interest across the BBB by receptor-mediated transcytosis [90-93]. In an elegant study, Hultqvist and collaborators fused two scFvs, binding to TfR, to the light chains of protofibril-selective anti-Aβ mAb158 and demonstrated that the fusion protein designated mAb158-scFv8D3 enters the brain after peripheral administration in APP-transgenic mice [90]. Fusion protein concentrations were 80-fold higher than those of unmodified mAb158. Notably, after three days, fusion protein concentrations in APP-transgenic mouse brains were 9-fold higher than in non-transgenic mice, suggesting that the fused antibody fragment bound specifically to soluble amyloid protofibrils in the brain [90]. Next, the radiolabeled 124I-RmAb158-scFv8D3 antibody fragment has been applied for PET imaging and shown to be a more sensitive reagent for detecting soluble Aβ protofibrils and monitoring the progression of the amyloid pathology compared to the small-molecule ligand 18F-florbetapir that binds to fibrillar amyloid plaques [91]. Subsequently, the authors designed another recombinant antibody fragment, named tribody and composed of two scFvs of the above-mentioned protofibril-selective mAb158 and Fab of anti-TfR monoclonal antibody 8D3 [94]. They demonstrated that such fragments, after labeling with iodine-124, may be used for PET imaging of amyloid aggregates [94]. Also, the authors generated a di-scFv 3D6-8D3 fragment and used it as a PET radioligand for visualization of Aβ in the brain of APP-transgenic mice [92]. Recently, the authors constructed multivalent antibodies using various numbers of heavy and light chains variable fragments of mAb158 and scFv8D3 and demonstrated that bispecific-multivalent recombinant antibodies were capable of crossing the BBB and reducing the amyloid load in 10-11-month-old Tg-ArcSwe mice after intravenous injection [95]. In 2023, the FDA granted accelerated authorization to the humanized version of the mAb158, lecanemab, for use in individuals with mild to moderate AD. Employing the above-mentioned strategies may enhance efficacy and reduce the cost of treatment with lecanemab.

Likewise, a single domain shark antibody VNAR fragment (TXB2), binding to both murine and human TfR1, was fused with the known anti-amyloid-β (Aβ) antibody, bapineuzumab (Bapi) [96]. After intravenous injection of the Bapi-anti-TfR VNAR fusion protein in APP-transgenic mice, Bapi was detected in the brain [96]. In addition, the authors fused another TfR1-specific VNAR, TXB4, to a tropomyosin receptor kinase B (TrkB) receptor agonist antibody and documented reduced neuronal loss in a mouse model of PD after intravenous injection [97]. TXB4-anti-TrkB recombinant antibody has been detected in TrkB-positive cells in the cortex and tyrosine hydroxylase (TH)- positive dopaminergic neurons in the substantia nigra pars compacta (SNc) [97]. These results indicated that anti-TfR1 VNARs may be successfully fused to therapeutic recombinant antibody fragments allowing them to cross BBB [96]. Likewise, an anti-human TfR VHH (Nb188) was selected from an immune anti-human TfR camelid VHH library, fused with neurotensin, and shown to induce hypothermia after intravenous injections in mice [98]. In the same report, the authors fused two anti-human TfR VHHs, Nb62 and Nb88, with anti-BACE-1 antibodies and demonstrated that both fusion proteins could reduce Aβ1-40 levels in the brain after systemic administration [98].

Also, single-domain fragments specifically binding to another receptor on BBB endothelial cells, insulin-like growth factor 1 receptor (IGF1R), were selected from an immune camelid VHH library and shown to bind to brain endothelial cells from different species: humans, rats, and mice [99]. The authors demonstrated that anti-IGF1R VHH fragments carrying conjugated galanin or neurotensin could induce a dose-dependent reduction in hyperalgesia and the core temperature, respectively [99, 100].

Rabbit single-domain VLL antibodies isolated from an immune anti-mouse bEnd. Three endothelial cells were conjugated with liposomes encapsulating a histone deacetylase inhibitor (HDACi) PAN and shown to cross the BBB after intravenous injection in the tail vein of CD1 mice [101].

Superparamagnetic iron oxide nanoparticles (SPIONs) have been explored for numerous biomedical applications, including drug delivery, tissue targeting and repair, iron replacement therapies, and contrast probes in MRI [102]. Liu and collaborators conjugated an Aβ oligomer-specific scFv antibody (W20) with SPIONs to develop an MRI contrast probe and demonstrated that W20-SPIONS could cross the BBB and specifically bind to oligomers in the transgenic mouse model of HD and PD [103]. Subsequently, the authors added the heptapeptide XD4, shown to activate the class A scavenger receptor (SR-A) on the microglia and promote phagocytosis of oligomeric Aβ, and evaluated the protective properties of the conjugate in APPswe/PS1dE9 transgenic mice. W20/XD4-SPIONs nanoparticles significantly ameliorated cognitive deficits and reduced Aβ burden, astrocytosis, microgliosis, and reactive oxygen species levels in the brains of treated mice [104, 105].

All these findings suggest that recombinant antibody fragments, alone or in the context of different nanoparticles, are promising tools for drug delivery into the brain.

CONCLUSION

Recombinant antibody fragments are promising alternatives to full-length immunoglobulins, creating big opportunities for the pharmaceutical industry. Many fragments in different formats (Fab, scFV, VHH, VLL, VNAR, etc.) are currently being evaluated in preclinical models and clinical trials. Recombinant antibody fragments have many advantages over other active and passive immunotherapy approaches. Their high specificity, superior affinity, and improved capacity to cross the BBB make it possible to use them at low concentrations, thus reducing adverse side effects observed frequently in patients after traditional immunotherapy. In addition, the lack of Fc-mediated activation of the peripheral immune cells and the microglia minimizes the risk of undesirable inflammatory response. Likewise, recombinant antibody fragments generally are not glycosylated, allowing their production in time- and cost-effective bacterial and yeast expression systems. All these characteristics make recombinant antibody fragments attractive molecules for the biotech industry for the development of novel diagnostic and therapeutic strategies for neurological disorders. The discovery of new tools for enhanced delivery of antibody fragments into the brain, the design of fusion peptides/proteins for targeting them to the cells/cell compartments of interest, and the application of AAV vector-mediated antibody gene therapy give us hope that in the nearest future, recombinant antibody fragments may become available for the prevention and treatment of several neurological disorders.

ACKNOWLEDGEMENTS

Declared none.

LIST OF ABBREVIATIONS

AAV Adeno-associated Viral Vector

AD Alzheimer’s Disease

Aβ Amyloid-beta

BBB Blood-brain Barrier

FDA Food and Drug Administration

FTD Frontotemporal Dementia

HD Huntington’s Disease

HDACi Histone Deacetylase Inhibitor

IGF1R Insulin-like Growth Factor 1 Receptor

MCI Mild Cognitive Impairment

MRI Magnetic Resonance Imaging

MRI/MRS Magnetic Resonance Imaging and Spectroscopy

MS Multiple Sclerosis

MTBD Microtubule-binding Domain

PD Parkinson’s Disease

PMs Polymeric Nanomicelles

PRR Proline-rich Region

scFv Single-chain Fragment Variable

SPIONs Superparamagnetic Iron Oxide Nanoparticles

TSEs Transmissible Spongiform Encephalopathies

VNARs Variable New Antigen Receptor

CONSENT FOR PUBLICATION

Not applicable.

FUNDING

Funding provided by DGAPA-UNAM (IN203322) to G.G. and (IN212323) to K.M.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

Table 1 Summary of recombinant antibody fragments used in AD, PD and HD pre-clinical models.

Recombinant Ab Fragment	Target/Disease	Key Findings	References	
Purified scFv-h3D6	Aβ, Alzheimer’s disease	Affinity maturation for enhanced binding.
Inhibition of Aβ uptake by human astrocytes.
Use of Pichia pastoris for improved production.
Co-localization with Aβ in endothelial cells.
Attenuation of amyloid pathology and cognitive impairment in APP-Tg mice.	[38]
[39]
[41]
[42]
[43-45]	
Purified scFvs: C6T, E1, D11C, ADTau2, ADTau4, ADTau6, AD-TDP3	Aβ, Tau, TDP-43 Alzheimer’s disease	Multiparameter blood biomarker panel for the early diagnosis of AD.	[46, 47]	
Purified camelid VHHs:
PrioAD12, PrioAD13	Aβ, Alzheimer’s disease	Early detection of Aβ in the retina and blood samples.	[48]	
Purified VHH: R3VQ	Aβ, Alzheimer’s disease	Crosses the BBB and binds to amyloid plaques.
Suitable for MRI.	[49, 50]	
Purified VHH: A2	Tau, Alzheimer’s disease	Crosses the BBB, diffuses in the brain and binds to intraneuronal tangles.	[49]	
AAV-expressed scFv NUsc1	Aβ, Alzheimer’s disease	Prevents oligomeric Aβ-induced memory impairment and reverses memory deficits in APP-Tg mice.	[51-53]	
scFv17	Aβ, Alzheimer’s disease	Reduces Aβ load in the brain of APP-Tg mice.	[54]	
AAV-expressed scFv-MC1	Tau, Alzheimer’s disease and other Tauopathies	Reduces tau pathology in Tg mice.	[55, 56]	
AAV-expressed AT8-scFv	Tau, Alzheimer’s disease and other Tauopathies	Crosses the BBB and enters neurons.	[57]	
VHH-E4-1 and VHH-Z70	Tau, Alzheimer’s disease and other Tauopathies	Inhibit Tau seeding in Tg mice.	[58]	
AAV-expressed scFv-EM-48	Tau, Alzheimer’s disease and other Tauopathies	Reduces Tau accumulation and ameliorates behavioral deficits in Tg mice.	[59, 60]	
AAV-expressed VHH-B9	BACE-1, Alzheimer’s disease	Reduces Aβ burden and cognitive deficits in Tg mice.	[62]	
Bispecific diabody,
iBsec1-Asec1a	BACE-1, α-secretase,
Alzheimer’s disease	Reduces Aβ burden and increases the survival of mice.	[65]	
Purified scFv-pF and scFv-PC.
Purified VHH Nbα-syn01	α-syn, Parkinson’s disease	Inhibit the seeding of α-syn aggregation and reduce α-syn toxicity in
SH-SY5Y cells.	[73-75]	
Purified scFv sMB08	α-syn, Parkinson’s disease	Enters neurons and co-localizes with α-syn aggregates.
Attenuates motor dysfunction in rats.	[75]	
Purified VHH Nbα-syn01	α-syn, Parkinson’s disease	Inhibit the seeding of α-syn aggregation and reduce α-syn toxicity in
SH-SY5Y cells.	[76]	
AAV-expressed scFv INT41	mhtt, Huntington’s disease	Ameliorates mhtt-induced cognitive impairment and reduces aggregate formation in the striatum of treated mice.	[86]
==== Refs
REFERENCES

1 Bird R. Walker B.W. Single chain antibody variable regions. Trends Biotechnol. 1991 9 1 132 137 10.1016/0167-7799(91)90044-I 1367550
2 Morrison S.L. In vitro antibodies: Strategies for production and application. Annu. Rev. Immunol. 1992 10 1 239 265 10.1146/annurev.iy.10.040192.001323 1590987
3 Plückthun A. Pack P. New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology 1997 3 2 83 105 10.1016/S1380-2933(97)00067-5 9237094
4 Ma H. O’Kennedy R. Recombinant antibody fragment production. Methods 2017 116 23 33 10.1016/j.ymeth.2016.11.008 27871972
5 Manoutcharian K. Perez-Garmendia R. Gevorkian G. Recombinant antibody fragments for neurodegenerative diseases. Curr. Neuropharmacol. 2017 15 5 779 788 10.2174/1570159X01666160930121647 27697033
6 Pietersz G.A. Wang X. Yap M.L. Lim B. Peter K. Therapeutic targeting in nanomedicine: The future lies in recombinant antibodies. Nanomedicine 2017 12 15 1873 1889 10.2217/nnm-2017-0043 28703636
7 Bélanger K. Iqbal U. Tanha J. MacKenzie R. Moreno M. Stanimirovic D. Single-domain antibodies as therapeutic and imaging agents for the treatment of CNS diseases. Antibodies 2019 8 2 27 10.3390/antib8020027 31544833
8 Bates A. Power C.A. David vs. Goliath: The structure, function, and clinical prospects of antibody fragments. Antibodies 2019 8 2 28 10.3390/antib8020028 31544834
9 Salvador J.P. Vilaplana L. Marco M.P. Nanobody: Outstanding features for diagnostic and therapeutic applications. Anal. Bioanal. Chem. 2019 411 9 1703 1713 10.1007/s00216-019-01633-4 30734854
10 Pothin E. Lesuisse D. Lafaye P. Brain delivery of single-domain antibodies: A focus on VHH and VNAR. Pharmaceutics 2020 12 10 937 10.3390/pharmaceutics12100937 33007904
11 Gao Y. Zhu J. Lu H. Single domain antibody-based vectors in the delivery of biologics across the blood–brain barrier: A review. Drug Deliv. Transl. Res. 2021 11 5 1818 1828 10.1007/s13346-020-00873-7 33155179
12 Roth K.D.R. Wenzel E.V. Ruschig M. Steinke S. Langreder N. Heine P.A. Schneider K.T. Ballmann R. Fühner V. Kuhn P. Schirrmann T. Frenzel A. Dübel S. Schubert M. Moreira G.M.S.G. Bertoglio F. Russo G. Hust M. Developing recombinant antibodies by phage display against infectious diseases and toxins for diagnostics and therapy. Front. Cell. Infect. Microbiol. 2021 11 697876 10.3389/fcimb.2021.697876 34307196
13 Ruiz-López E. Schuhmacher A.J. Transportation of single-domain antibodies through the blood–brain barrier. Biomolecules 2021 11 8 1131 10.3390/biom11081131 34439797
14 Naidoo D.B. Chuturgoon A.A. The potential of nanobodies for COVID-19 diagnostics and therapeutics. Mol. Diagn. Ther. 2023 27 2 193 226 10.1007/s40291-022-00634-x 36656511
15 Fuller J.P. Stavenhagen J.B. Teeling J.L. New roles for Fc receptors in neurodegeneration-the impact on Immunotherapy for Alzheimer’s Disease. Front. Neurosci. 2014 8 235 10.3389/fnins.2014.00235 25191216
16 Sun X. Yu X. Zhu J. Li L. Zhang L. Huang Y. Liu D. Ji M. Sun X. Zhang L. Zhou W. Zhang D. Jiao J. Liu R. Fc effector of anti-Aβ antibody induces synapse loss and cognitive deficits in Alzheimer’s disease-like mouse model. Signal Transduct. Target. Ther. 2023 8 1 30 10.1038/s41392-022-01273-8 36693826
17 Huang L. Su X. Federoff H. Single-chain fragment variable passive immunotherapies for neurodegenerative diseases. Int. J. Mol. Sci. 2013 14 9 19109 19127 10.3390/ijms140919109 24048248
18 Lulu S. Waubant E. Humoral-targeted immunotherapies in multiple sclerosis. Neurotherapeutics 2013 10 1 34 43 10.1007/s13311-012-0164-3 23208729
19 Cardinale A. Merlo D. Giunchedi P. Biocca S. Therapeutic application of intrabodies against age-related neurodegenerative disorders. Curr. Pharm. Des. 2014 20 38 6028 6036 10.2174/1381612820666140314121444 24641233
20 Wootla B. Watzlawik J.O. Stavropoulos N. Wittenberg N.J. Dasari H. Abdelrahim M.A. Henley J.R. Oh S.H. Warrington A.E. Rodriguez M. Recent advances in monoclonal antibody therapies for multiple sclerosis. Expert Opin. Biol. Ther. 2016 16 6 827 839 10.1517/14712598.2016.1158809 26914737
21 Frontzek K. Aguzzi A. Recent developments in antibody therapeutics against prion disease. Emerg. Top. Life Sci. 2020 4 2 169 173 10.1042/ETLS20200002 32633322
22 Jamwal S. Elsworth J.D. Rahi V. Kumar P. Gene therapy and immunotherapy as promising strategies to combat Huntington’s disease-associated neurodegeneration: emphasis on recent updates and future perspectives. Expert Rev. Neurother. 2020 20 11 1123 1141 10.1080/14737175.2020.1801424 32720531
23 Panza F. Lozupone M. Seripa D. Daniele A. Watling M. Giannelli G. Imbimbo B.P. Development of disease-modifying drugs for frontotemporal dementia spectrum disorders. Nat. Rev. Neurol. 2020 16 4 213 228 10.1038/s41582-020-0330-x 32203398
24 Haddad H.W. Malone G.W. Comardelle N.J. Degueure A.E. Poliwoda S. Kaye R.J. Murnane K.S. Kaye A.M. Kaye A.D. Aduhelm, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer’s Disease: A comprehensive review. Health Psychol. Res. 2022 10 2 37023 10.52965/001c.37023 35910244
25 Menon S. Armstrong S. Hamzeh A. Visanji N.P. Sardi S.P. Tandon A. Alpha-synuclein targeting therapeutics for Parkinson’s Disease and related synucleinopathies. Front. Neurol. 2022 13 852003 10.3389/fneur.2022.852003 35614915
26 Bateman R.J. Cummings J. Schobel S. Salloway S. Vellas B. Boada M. Black S.E. Blennow K. Fontoura P. Klein G. Assunção S.S. Smith J. Doody R.S. Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer’s disease. Alzheimers Res. Ther. 2022 14 1 178 10.1186/s13195-022-01110-8 36447240
27 De Genst E. Messer A. Dobson C.M. Antibodies and protein misfolding: From structural research tools to therapeutic strategies. Biochim. Biophys. Acta. Proteins Proteomics 2014 1844 11 1907 1919 10.1016/j.bbapap.2014.08.016 25194824
28 Valera E. Spencer B. Masliah E. Immunotherapeutic approaches targeting amyloid-β, α-synuclein, and tau for the treatment of neurodegenerative disorders. Neurotherapeutics 2016 13 1 179 189 10.1007/s13311-015-0397-z 26494242
29 Chia K.Y. Ng K.Y. Koh R.Y. Chye S.M. Single-chain Fv antibodies for targeting neurodegenerative diseases. CNS Neurol. Disord. Drug Targets 2018 17 9 671 679 10.2174/1871527317666180315161626 29546836
30 Messer A. Butler D.C. Optimizing intracellular antibodies (intrabodies/nanobodies) to treat neurodegenerative disorders. Neurobiol. Dis. 2020 134 104619 10.1016/j.nbd.2019.104619 31669671
31 Benn J.A. Mukadam A.S. McEwan W.A. Targeted protein degradation using intracellular antibodies and its application to neurodegenerative disease. Semin. Cell Dev. Biol. 2022 126 138 149 10.1016/j.semcdb.2021.09.012 34654628
32 Iqbal K. Grundke-Iqbal I. Alzheimer’s disease, a multifactorial disorder seeking multitherapies. Alzheimers Dement. 2010 6 5 420 424 10.1016/j.jalz.2010.04.006 20813343
33 Gong C.X. Liu F. Iqbal K. Multifactorial hypothesis and multi-targets for Alzheimer’s Disease. J. Alzheimers Dis. 2018 64 s1 S107 S117 10.3233/JAD-179921 29562523
34 Boyd R.J. Avramopoulos D. Jantzie L.L. McCallion A.S. Neuroinflammation represents a common theme amongst genetic and environmental risk factors for Alzheimer and Parkinson diseases. J. Neuroinflammation 2022 19 1 223 10.1186/s12974-022-02584-x 36076238
35 Penke B. Szűcs M. Bogár F. New pathways identify novel drug targets for the prevention and treatment of Alzheimer’s Disease. Int. J. Mol. Sci. 2023 24 6 5383 10.3390/ijms24065383 36982456
36 Selkoe D.J. Altered structural proteins in plaques and tangles: What do they tell us about the biology of Alzheimer’s disease? Neurobiol. Aging 1986 7 6 425 432 10.1016/0197-4580(86)90055-2 3104810
37 LaFerla F.M. Green K.N. Oddo S. Intracellular amyloid-β in Alzheimer’s disease. Nat. Rev. Neurosci. 2007 8 7 499 509 10.1038/nrn2168 17551515
38 Montoliu-Gaya L. Murciano-Calles J. Martinez J.C. Villegas S. Towards the improvement in stability of an anti-Aβ single-chain variable fragment, scFv-h3D6, as a way to enhance its therapeutic potential. Amyloid 2017 24 3 167 175 10.1080/13506129.2017.1348347 28699800
39 Montoliu-Gaya L. Mulder S.D. Herrebout M.A.C. Baayen J.C. Villegas S. Veerhuis R. Aβ-oligomer uptake and the resulting inflammatory response in adult human astrocytes are precluded by an anti-Aβ single chain variable fragment in combination with an apoE mimetic peptide. Mol. Cell. Neurosci. 2018 89 49 59 10.1016/j.mcn.2018.03.015 29625180
40 Söllvander S. Nikitidou E. Brolin R. Söderberg L. Sehlin D. Lannfelt L. Erlandsson A. Accumulation of amyloid-β by astrocytes result in enlarged endosomes and microvesicle-induced apoptosis of neurons. Mol. Neurodegener. 2016 11 1 38 10.1186/s13024-016-0098-z 27176225
41 Montoliu-Gaya L. Esquerda-Canals G. Bronsoms S. Villegas S. Production of an anti-Aβ antibody fragment in Pichia pastoris and in vitro and in vivo validation of its therapeutic effect. PLoS One 2017 12 8 e0181480 10.1371/journal.pone.0181480 28771492
42 Esquerda-Canals G. Martí-Clúa J. Villegas S. Pharmacokinetic parameters and mechanism of action of an efficient anti-Aβ single chain antibody fragment. PLoS One 2019 14 5 e0217793 10.1371/journal.pone.0217793 31150495
43 Esquerda-Canals G. Roda A.R. Martí-Clúa J. Montoliu-Gaya L. Rivera-Hernández G. Villegas S. Treatment with scFv-h3D6 prevented neuronal loss and improved spatial memory in young 3xTg-AD mice by reducing the intracellular amyloid-β burden. J. Alzheimers Dis. 2019 70 4 1069 1091 10.3233/JAD-190484 31306135
44 Güell-Bosch J. Lope-Piedrafita S. Esquerda-Canals G. Montoliu-Gaya L. Villegas S. Progression of Alzheimer’s disease and effect of scFv-h3D6 immunotherapy in the 3xTg-AD mouse model: An in vivo longitudinal study using Magnetic Resonance Imaging and Spectroscopy. NMR Biomed. 2020 33 5 e4263 10.1002/nbm.4263 32067292
45 Roda A.R. Montoliu-Gaya L. Serra-Mir G. Villegas S. Both amyloid-β peptide and tau protein are affected by an anti-amyloid-β antibody fragment in elderly 3xTg-AD mice. Int. J. Mol. Sci. 2020 21 18 6630 10.3390/ijms21186630 32927795
46 Williams S.M. Schulz P. Rosenberry T.L. Caselli R.J. Sierks M.R. Blood-based oligomeric and other protein variant biomarkers to facilitate pre-symptomatic diagnosis and staging of Alzheimer’s disease. J. Alzheimers Dis. 2017 58 1 23 35 10.3233/JAD-161116 28372328
47 Cho H.J. Schulz P. Venkataraman L. Caselli R.J. Sierks M.R. Sex-specific multiparameter blood test for the early diagnosis of Alzheimer’s Disease. Int. J. Mol. Sci. 2022 23 24 15670 10.3390/ijms232415670 36555310
48 Habiba U. Descallar J. Kreilaus F. Adhikari U.K. Kumar S. Morley J.W. Bui B.V. Koronyo-Hamaoui M. Tayebi M. Detection of retinal and blood Aβ oligomers with nanobodies. Alzheimers Dement. 2021 13 1 e12193 10.1002/dad2.12193 33977118
49 Li T. Vandesquille M. Koukouli F. Dudeffant C. Youssef I. Lenormand P. Ganneau C. Maskos U. Czech C. Grueninger F. Duyckaerts C. Dhenain M. Bay S. Delatour B. Lafaye P. Camelid single-domain antibodies: A versatile tool for in vivo imaging of extracellular and intracellular brain targets. J. Control. Release 2016 243 1 10 10.1016/j.jconrel.2016.09.019 27671875
50 Vandesquille M. Li T. Po C. Ganneau C. Lenormand P. Dudeffant C. Czech C. Grueninger F. Duyckaerts C. Delatour B. Dhenain M. Lafaye P. Bay S. Chemically-defined camelid antibody bioconjugate for the magnetic resonance imaging of Alzheimer’s disease. MAbs 2017 9 6 1016 1027 10.1080/19420862.2017.1342914 28657418
51 Sebollela A. Cline E.N. Popova I. Luo K. Sun X. Ahn J. Barcelos M.A. Bezerra V.N. Lyra e Silva N.M. Patel J. Pinheiro N.R. Qin L.A. Kamel J.M. Weng A. DiNunno N. Bebenek A.M. Velasco P.T. Viola K.L. Lacor P.N. Ferreira S.T. Klein W.L. A human scFv antibody that targets and neutralizes high molecular weight pathogenic amyloid‐β oligomers. J. Neurochem. 2017 142 6 934 947 10.1111/jnc.14118 28670737
52 Cline E.N. Bicca M.A. Viola K.L. Klein W.L. The amyloid-β oligomer hypothesis: Beginning of the third decade. J. Alzheimers Dis. 2018 64 S1 S567 S610 10.3233/JAD-179941 29843241
53 Selles M.C. Fortuna J.T.S. Cercato M.C. Santos L.E. Domett L. Bitencourt A.L.B. Carraro M.F. Souza A.S. Janickova H. Azevedo C.V. Campos H.C. de Souza J.M. Alves-Leon S. Prado V.F. Prado M.A.M. Epstein A.L. Salvetti A. Longo B.M. Arancio O. Klein W.L. Sebollela A. De Felice F.G. Jerusalinsky D.A. Ferreira S.T. AAV-mediated neuronal expression of an scFv antibody selective for Aβ oligomers protects synapses and rescues memory in Alzheimer models. Mol. Ther. 2023 31 2 409 419 10.1016/j.ymthe.2022.11.002 36369741
54 Hu M. Zhang J. Yang J. Cao Y. Qi J. A novel scFv Anti-Aβ antibody reduces pathological impairments in APP/PS1 transgenic mice via modulation of inflammatory cytokines and aβ-related enzymes. J. Mol. Neurosci. 2018 66 1 1 9 10.1007/s12031-018-1139-6 30062438
55 Vitale F. Giliberto L. Ruiz S. Steslow K. Marambaud P. d’Abramo C. Anti-tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice. Acta Neuropathol. Commun. 2018 6 1 82 10.1186/s40478-018-0585-2 30134961
56 Vitale F. Ortolan J. Volpe B.T. Marambaud P. Giliberto L. d’Abramo C. Intramuscular injection of vectorized-scFvMC1 reduces pathological tau in two different tau transgenic models. Acta Neuropathol. Commun. 2020 8 1 126 10.1186/s40478-020-01003-7 32762731
57 Zhang Y. Qian L. Kuang Y. Liu J. Wang D. Xie W. Zhang L. Fu L. An adeno-associated virus-mediated immunotherapy for Alzheimer’s disease. Mol. Immunol. 2022 144 26 34 10.1016/j.molimm.2022.02.006 35172225
58 Danis C. Dupré E. Zejneli O. Caillierez R. Arrial A. Bégard S. Mortelecque J. Eddarkaoui S. Loyens A. Cantrelle F.X. Hanoulle X. Rain J.C. Colin M. Buée L. Landrieu I. Inhibition of Tau seeding by targeting Tau nucleation core within neurons with a single domain antibody fragment. Mol. Ther. 2022 30 4 1484 1499 10.1016/j.ymthe.2022.01.009 35007758
59 Guo T. Noble W. Hanger D.P. Roles of tau protein in health and disease. Acta Neuropathol. 2017 133 5 665 704 10.1007/s00401-017-1707-9 28386764
60 Spencer B. Brüschweiler S. Sealey-Cardona M. Rockenstein E. Adame A. Florio J. Mante M. Trinh I. Rissman R.A. Konrat R. Masliah E. Selective targeting of 3 repeat Tau with brain penetrating single chain antibodies for the treatment of neurodegenerative disorders. Acta Neuropathol. 2018 136 1 69 87 10.1007/s00401-018-1869-0 29934874
61 Panza F. Lozupone M. Solfrizzi V. Sardone R. Piccininni C. Dibello V. Stallone R. Giannelli G. Bellomo A. Greco A. Daniele A. Seripa D. Logroscino G. Imbimbo B.P. BACE inhibitors in clinical development for the treatment of Alzheimer’s disease. Expert Rev. Neurother. 2018 18 11 847 857 10.1080/14737175.2018.1531706 30277096
62 Marino M. Zhou L. Rincon M.Y. Callaerts-Vegh Z. Verhaert J. Wahis J. Creemers E. Yshii L. Wierda K. Saito T. Marneffe C. Voytyuk I. Wouters Y. Dewilde M. Duqué S.I. Vincke C. Levites Y. Golde T.E. Saido T.C. Muyldermans S. Liston A. De Strooper B. Holt M.G. AAV‐mediated delivery of an anti‐BACE1 VHH alleviates pathology in an Alzheimer’s disease model. EMBO Mol. Med. 2022 14 4 e09824 10.15252/emmm.201809824 35352880
63 Fahrenholz F. Alpha-secretase as a therapeutic target. Curr. Alzheimer Res. 2007 4 4 412 417 10.2174/156720507781788837 17908044
64 Lichtenthaler S.F. Tschirner S.K. Steiner H. Secretases in Alzheimer’s disease: Novel insights into proteolysis of APP and TREM2. Curr. Opin. Neurobiol. 2022 72 101 110 10.1016/j.conb.2021.09.003 34689040
65 He P. Xin W. Schulz P. Sierks M.R. Bispecific antibody fragment targeting app and inducing α-site cleavage restores neuronal health in an alzheimer’s mouse model. Mol. Neurobiol. 2019 56 11 7420 7432 10.1007/s12035-019-1597-z 31041656
66 Zhao L. Meng F. Li Y. Liu S. Xu M. Chu F. Li C. Yang X. Luo L. Multivalent nanobody conjugate with rigid, reactive oxygen species scavenging scaffold for multi‐target therapy of Alzheimer’s Disease. Adv. Mater. 2023 35 17 2210879 10.1002/adma.202210879 36786375
67 Saleh M. Markovic M. Olson K.E. Gendelman H.E. Mosley R.L. Therapeutic strategies for immune transformation in parkinson’s disease. J. Parkinsons Dis. 2022 12 s1 S201 S222 10.3233/JPD-223278 35871362
68 Massey A. Boag M. Magnier A. Bispo D. Khoo T. Pountney D. Glymphatic system dysfunction and sleep disturbance may contribute to the pathogenesis and progression of Parkinson’s Disease. Int. J. Mol. Sci. 2022 23 21 12928 10.3390/ijms232112928 36361716
69 Dong-Chen X. Yong C. Yang X. Chen-Yu S. Li-Hua P. Signaling pathways in Parkinson’s disease: Molecular mechanisms and therapeutic interventions. Signal Transduct. Target. Ther. 2023 8 1 73 10.1038/s41392-023-01353-3 36810524
70 Forloni G. Alpha synuclein: Neurodegeneration and inflammation. Int. J. Mol. Sci. 2023 24 6 5914 10.3390/ijms24065914 36982988
71 Castonguay A-M. Gravel C. Lévesque M. Treating Parkinson’s Disease with antibodies: Previous studies and future directions. J. Parkinsons Dis. 2021 11 1 71 92 10.3233/JPD-202221 33104039
72 Knecht L. Folke J. Dodel R. Ross J.A. Albus A. Alpha-synuclein immunization strategies for synucleinopathies in clinical studies: A biological perspective. Neurotherapeutics 2022 19 5 1489 1502 10.1007/s13311-022-01288-7 36083395
73 Gupta V. Salim S. Hmila I. Vaikath N.N. Sudhakaran I.P. Ghanem S.S. Majbour N.K. Abdulla S.A. Emara M.M. Abdesselem H.B. Lukacsovich T. Erskine D. El-Agnaf O.M.A. Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity. Sci. Rep. 2020 10 1 8137 10.1038/s41598-020-65035-8 32424162
74 Gupta V. Sudhakaran I.P. Islam Z. Vaikath N.N. Hmila I. Lukacsovich T. Kolatkar P.R. El-Agnaf O.M.A. Expression, purification and characterization of α-synuclein fibrillar specific scFv from inclusion bodies. PLoS One 2020 15 11 e0241773 10.1371/journal.pone.0241773 33156828
75 Fassler M. Benaim C. George J. A single chain fragment variant binding misfolded alpha-synuclein exhibits neuroprotective and antigen-specific anti-inflammatory properties. Cells 2022 11 23 3822 10.3390/cells11233822 36497081
76 Hmila I. Vaikath N.N. Majbour N.K. Erskine D. Sudhakaran I.P. Gupta V. Ghanem S.S. Islam Z. Emara M.M. Abdesselem H.B. Kolatkar P.R. Achappa D.K. Vinardell T. El-Agnaf O.M.A. Novel engineered nanobodies specific for N-terminal region of alpha-synuclein recognize Lewy‐body pathology and inhibit in-vitro seeded aggregation and toxicity. FEBS J. 2022 289 15 4657 4673 10.1111/febs.16376 35090199
77 Cookson M.R. LRRK2 pathways leading to neurodegeneration. Curr. Neurol. Neurosci. Rep. 2015 15 7 42 10.1007/s11910-015-0564-y 26008812
78 Gilligan P. Inhibitors of leucine-rich repeat kinase 2 (LRRK2): Progress and promise for the treatment of Parkinson’s disease. Curr. Top. Med. Chem. 2015 15 10 927 938 10.2174/156802661510150328223655 25832719
79 Mata I. Salles P. Cornejo-Olivas M. Saffie P. Ross O.A. Reed X. Bandres-Ciga S. LRRK2: Genetic mechanisms vs genetic subtypes. Handb. Clin. Neurol. 2023 193 133 154 10.1016/B978-0-323-85555-6.00018-7 36803807
80 Taymans J.M. Greggio E. LRRK2 kinase inhibition as a therapeutic strategy for Parkinson’s disease, where do we stand? Curr. Neuropharmacol. 2016 14 3 214 225 10.2174/1570159X13666151030102847 26517051
81 Singh R.K. Soliman A. Guaitoli G. Störmer E. von Zweydorf F. Dal Maso T. Oun A. Van Rillaer L. Schmidt S.H. Chatterjee D. David J.A. Pardon E. Schwartz T.U. Knapp S. Kennedy E.J. Steyaert J. Herberg F.W. Kortholt A. Gloeckner C.J. Versées W. Nanobodies as allosteric modulators of Parkinson’s disease–associated LRRK2. Proc. Natl. Acad. Sci. 2022 119 9 e2112712119 10.1073/pnas.2112712119 35217606
82 Rüb U. Vonsattel J.P.G. Heinsen H. Korf H.W. The neuropathology of Huntington’s disease: Classical findings, recent developments and correlation to functional neuroanatomy. Adv. Anat. Embryol. Cell Biol. 2015 217 1 146 10.1007/978-3-319-19285-7 26767207
83 Palaiogeorgou A. Papakonstantinou E. Golfinopoulou R. Sigala M. Mitsis T. Papageorgiou L. Diakou I. Pierouli K. Dragoumani K. Spandidos D. Bacopoulou F. Chrousos G. Eliopoulos E. Vlachakis D. Recent approaches on Huntington’s disease (Review). Biomed. Rep. 2022 18 1 5 10.3892/br.2022.1587 36544856
84 Khoshnan A. Ou S. Ko J. Patterson P.H. Antibodies and intrabodies against huntingtin: production and screening of monoclonals and single-chain recombinant forms. Methods Mol. Biol. 2013 1010 231 251 10.1007/978-1-62703-411-1_15 23754229
85 Denis H.L. David L.S. Cicchetti F. Antibody-based therapies for Huntington’s disease: Current status and future directions. Neurobiol. Dis. 2019 132 104569 10.1016/j.nbd.2019.104569 31398458
86 Amaro I.A. Henderson L.A. An intrabody drug (rAAV6-INT41) reduces the binding of N-terminal huntingtin fragment(s) to DNA to basal levels in PC12 cells and delays cognitive loss in the R6/2 animal model. J. Neurodegener. Dis. 2016 2016 1 10 10.1155/2016/7120753 27595037
87 Perche F. Uchida S. Akiba H. Lin C.Y. Ikegami M. Dirisala A. Nakashima T. Itaka K. Tsumoto K. Kataoka K. Improved brain expression of anti-amyloid β scFv by complexation of mRNA including a secretion sequence with PEG-based block catiomer. Curr. Alzheimer Res. 2017 14 3 295 302 10.2174/1567205013666161108110031 27829339
88 Xie J. Gonzalez-Carter D. Tockary T.A. Nakamura N. Xue Y. Nakakido M. Akiba H. Dirisala A. Liu X. Toh K. Yang T. Wang Z. Fukushima S. Li J. Quader S. Tsumoto K. Yokota T. Anraku Y. Kataoka K. Dual-sensitive nanomicelles enhancing systemic delivery of therapeutically active antibodies specifically into the brain. ACS Nano 2020 14 6 6729 6742 10.1021/acsnano.9b09991 32431145
89 Tsitokana M.E. Lafon P.A. Prézeau L. Pin J.P. Rondard P. Targeting the brain with single-domain antibodies: Greater potential than stated so far? Int. J. Mol. Sci. 2023 24 3 2632 10.3390/ijms24032632 36768953
90 Hultqvist G. Syvänen S. Fang X.T. Lannfelt L. Sehlin D. Bivalent brain shuttle increases antibody uptake by monovalent binding to the transferrin receptor. Theranostics 2017 7 2 308 318 10.7150/thno.17155 28042336
91 Meier S.R. Syvänen S. Hultqvist G. Fang X.T. Roshanbin S. Lannfelt L. Neumann U. Sehlin D. Antibody-based in vivo PET imaging detects amyloid-β reduction in alzheimer transgenic mice after BACE-1 inhibition. J. Nucl. Med. 2018 59 12 1885 1891 10.2967/jnumed.118.213140 29853653
92 Fang X.T. Hultqvist G. Meier S.R. Antoni G. Sehlin D. Syvänen S. High detection sensitivity with antibody-based PET radioligand for amyloid beta in brain. Neuroimage 2019 184 881 888 10.1016/j.neuroimage.2018.10.011 30300753
93 Stocki P. Szary J. Rasmussen C.L.M. Demydchuk M. Northall L. Logan D.B. Gauhar A. Thei L. Moos T. Walsh F.S. Rutkowski J.L. Blood‐brain barrier transport using a high affinity, brain‐selective VNAR antibody targeting transferrin receptor 1. FASEB J. 2021 35 2 e21172 10.1096/fj.202001787R 33241587
94 Syvänen S. Fang X.T. Hultqvist G. Meier S.R. Lannfelt L. Sehlin D. A bispecific Tribody PET radioligand for visualization of amyloid-beta protofibrils – a new concept for neuroimaging. Neuroimage 2017 148 55 63 10.1016/j.neuroimage.2017.01.004 28069541
95 Rofo F. Meier S.R. Metzendorf N.G. Morrison J.I. Petrovic A. Syvänen S. Sehlin D. Hultqvist G. A brain-targeting bispecific-multivalent antibody clears soluble amyloid-beta aggregates in alzheimer’s disease mice. Neurotherapeutics 2022 19 5 1588 1602 10.1007/s13311-022-01283-y 35939261
96 Sehlin D. Stocki P. Gustavsson T. Hultqvist G. Walsh F.S. Rutkowski J.L. Syvänen S. Brain delivery of biologics using a cross-species reactive transferrin receptor 1 VNAR shuttle. FASEB J. 2020 34 10 13272 13283 10.1096/fj.202000610RR 32779267
97 Clarke E. Stocki P. Sinclair E.H. Gauhar A. Fletcher E.J.R. Krawczun-Rygmaczewska A. Duty S. Walsh F.S. Doherty P. Rutkowski J.L. A single domain shark antibody targeting the transferrin receptor 1 delivers a TrkB agonist antibody to the brain and provides full neuroprotection in a mouse model of Parkinson’s Disease. Pharmaceutics 2022 14 7 1335 10.3390/pharmaceutics14071335 35890231
98 Wouters Y. Jaspers T. Rué L. Serneels L. De Strooper B. Dewilde M. VHHs as tools for therapeutic protein delivery to the central nervous system. Fluids Barriers CNS 2022 19 1 79 10.1186/s12987-022-00374-4 36192747
99 Alata W. Yogi A. Brunette E. Delaney C.E. Faassen H. Hussack G. Iqbal U. Kemmerich K. Haqqani A.S. Moreno M.J. Stanimirovic D.B. Targeting insulin‐like growth factor‐1 receptor (IGF1R) for brain delivery of biologics. FASEB J. 2022 36 3 e22208 10.1096/fj.202101644R 35192204
100 Yogi A. Hussack G. van Faassen H. Haqqani A.S. Delaney C.E. Brunette E. Sandhu J.K. Hewitt M. Sulea T. Kemmerich K. Stanimirovic D.B. Brain delivery of IGF1R5, a single-domain antibody targeting insulin-like growth factor-1 receptor. Pharmaceutics 2022 14 7 1452 10.3390/pharmaceutics14071452 35890347
101 Aguiar S.I. Días J.N.R. André A.S. Silva M.L. Martins D. Carrapiço B. Castanho M. Carriço J. Cavaco M. Gaspar M.M. Nobre R.J. Pereira de Almeida L. Oliveira S. Gano L. Correia J.D.G. Barbas C. III Gonçalves J. Neves V. Aires-da-Silva F. Highly specific blood-brain barrier transmigrating single-domain antibodies selected by an in vivo phage display screening. Pharmaceutics 2021 13 10 1598 10.3390/pharmaceutics13101598 34683891
102 Vangijzegem T. Lecomte V. Ternad I. Van Leuven L. Muller R.N. Stanicki D. Laurent S. Superparamagnetic iron oxide nanoparticles (SPION): From fundamentals to state-of-the-art innovative applications for cancer therapy. Pharmaceutics 2023 15 1 236 10.3390/pharmaceutics15010236 36678868
103 Liu X. Lu S. Liu D. Zhang L. Zhang L. Yu X. Liu R. ScFv-conjugated superparamagnetic iron oxide nanoparticles for MRI-based diagnosis in transgenic mouse models of Parkinson’s and Huntington’s diseases. Brain Res. 2019 1707 141 153 10.1016/j.brainres.2018.11.034 30481502
104 Liu X.G. Zhang L. Lu S. Liu D.Q. Zhang L.X. Yu X.L. Liu R.T. Multifunctional superparamagnetic iron oxide nanoparticles conjugated with Aβ oligomer-specific scFv antibody and class a scavenger receptor activator show early diagnostic potentials for Alzheimer’s Disease. Int. J. Nanomedicine 2020 15 4919 4932 10.2147/IJN.S240953 32764925
105 Liu X. Zhang L. Lu S. Liu D. Huang Y. Zhu J. Zhou W. Yu X. Liu R. Superparamagnetic iron oxide nanoparticles conjugated with Aβ oligomer-specific scFv antibody and class A scavenger receptor activator show therapeutic potentials for Alzheimer’s disease. J. Nanobiotechnology 2020 18 1 160 10.1186/s12951-020-00723-1 33160377
